Using NLRP3 KO mice, it was also reported that NLRP3 inflammasome activation is required for fibrosis development in non-alcoholic fatty liver disease (NAFLD) [75]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.